Syringe and Vials Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse. The Food and Drug Administration ...
Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone extended-release injectable suspension for subcutaneous use, a schizophrenia treatment. "The ...
SLOUGH, England and RICHMOND, Va., Nov. 19, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that PERSERIS™ (risperidone) for extended-release injectable suspension is now available in ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Citrome: Hello, ...
Presented data include population pharmacokinetic (PopPK) modeling to investigate dosing conversion strategies for switching patients to a once-monthly or once every two-months subcutaneous dose of ...
SAN DIEGO and CUPERTINO, Calif., July 12, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous ...
SAN DIEGO, May 30, 2012--Zogenix Inc. (Nasdaq: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback